

Jean-Claude Schmit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10734265/publications.pdf>

Version: 2024-02-01

50
papers

2,618
citations

257101

24
h-index

197535

49
g-index

50
all docs

50
docs citations

50
times ranked

2863
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	1.9	385
2	COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. <i>Nucleic Acids Research</i> , 2014, 42, e144-e144.	6.5	288
3	Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009, 200, 1503-1508.	1.9	213
4	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	2.9	135
5	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. <i>Retrovirology</i> , 2013, 10, 7.	0.9	129
6	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009, 6, 49.	0.9	114
7	Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). <i>Aids</i> , 1996, 10, 995-999.	1.0	111
8	European recommendations for the clinical use of HIV drug resistance testing: 2011 update. <i>AIDS Reviews</i> , 2011, 13, 77-108.	0.5	106
9	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2109-2117.	1.4	101
10	Quantification of HIV-1 RNA in Plasma: Comparable Results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor Test. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 127-139.	0.3	95
11	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. <i>Aids</i> , 1998, 12, 2007-2015.	1.0	77
12	Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. <i>Biochemical Pharmacology</i> , 2012, 84, 1366-1380.	2.0	77
13	Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. <i>Journal of Virological Methods</i> , 1995, 52, 121-132.	1.0	63
14	Uncommon Mutations at Residue Positions Critical for Enfuvirtide (T-20) Resistance in Enfuvirtide-Naive Patients Infected With Subtype B and Non-B HIV-1 Strains. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 134-139.	0.9	50
15	Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. <i>World Journal of Gastroenterology</i> , 2008, 14, 1237.	1.4	48
16	Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2001, 39, 454-459.	1.8	43
17	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. <i>BMC Infectious Diseases</i> , 2014, 14, 407.	1.3	43
18	HIV-1 subtypes in Luxembourg, 1983-2000. <i>Aids</i> , 2002, 16, 2461-2467.	1.0	38

#	ARTICLE	IF	CITATIONS
19	HIV-1 Tropism Determination Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG. PLoS ONE, 2013, 8, e60566.	1.1	36
20	Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. Journal of Virological Methods, 1998, 73, 77-82.	1.0	34
21	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. PLoS ONE, 2014, 9, e94495.	1.1	32
22	Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. Aids, 2000, 14, 469.	1.0	28
23	Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs. , 2000, 24, 223-258.		27
24	Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrobial Agents and Chemotherapy, 2001, 45, 893-900.	1.4	25
25	Engineering and screening the N-terminus of chemokines for drug discovery. Biochemical Pharmacology, 2011, 82, 1438-1456.	2.0	25
26	A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. BMC Public Health, 2011, 11, 351.	1.2	24
27	Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller. Aids, 2016, 30, 377-382.	1.0	21
28	Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1031-1041.	1.9	20
29	Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. Aids, 1996, 10, F61-F66.	1.0	18
30	HIV Type 1polGene Diversity and Archived Nevirapine Resistance Mutation in Pregnant Women in Rwanda. AIDS Research and Human Retroviruses, 2004, 20, 279-283.	0.5	17
31	Phages and HIV-1: From Display to Interplay. International Journal of Molecular Sciences, 2012, 13, 4727-4794.	1.8	17
32	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. PLoS ONE, 2013, 8, e61436.	1.1	17
33	Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg. AIDS Research and Human Retroviruses, 2015, 31, 554-558.	0.5	17
34	Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. Aids, 2001, 15, 553-561.	1.0	16
35	Impact of the HIV-1 env Genetic Context outside HR1â€“HR2 on Resistance to the Fusion Inhibitor Enfuvirtide and Viral Infectivity in Clinical Isolates. PLoS ONE, 2011, 6, e21535.	1.1	14
36	Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope. Molecular Immunology, 2008, 45, 1366-1373.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. <i>Journal of Epidemiology and Community Health</i> , 2012, 66, 64-68.	2.0	12
38	Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 214-220.	1.1	10
39	Rescue of HIV-1 long-time archived X4 strains to escape maraviroc. <i>Antiviral Research</i> , 2011, 92, 488-492.	1.9	10
40	Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: validation through agonist and antagonist docking. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 1274-1289.	2.0	10
41	Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy. <i>Antiviral Therapy</i> , 1998, 3, 81-88.	0.6	10
42	Prevalence of HIV co-receptor polymorphisms in HIV-infected patients and uninfected volunteers in Luxembourg. <i>HIV Clinical Trials</i> , 2002, 3, 195-201.	2.0	9
43	Predominance of the heterozygous $\Delta 5$ deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface. <i>Journal of the International AIDS Society</i> , 2019, 22, e25384.	1.2	9
44	Genotypic Correlates of Resistance to HIV-1 Protease Inhibitors on Longitudinal Data: The Role of Secondary Mutations. <i>Antiviral Therapy</i> , 2002, 6, 239-248.	0.6	8
45	Selection of a CXCR4 antagonist from a human heavy chain CDR3-derived phage library. <i>FEBS Journal</i> , 2011, 278, 2867-2878.	2.2	6
46	Active Components from <i>Cassia abbreviata</i> Prevent HIV-1 Entry by Distinct Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5052.	1.8	6
47	Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure. <i>Journal of Medical Virology</i> , 2002, 67, 312-319.	2.5	4
48	The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission. <i>PLoS ONE</i> , 2016, 11, e0161596.	1.1	4
49	A new recombinant virus system for the study of HIV-1 entry and inhibition. <i>Journal of Virological Methods</i> , 2006, 131, 99-104.	1.0	3
50	Longitudinal Use of a Line Probe Assay for Human Immunodeficiency Virus Type 1 Protease Predicts Phenotypic Resistance and Clinical Progression in Patients Failing Highly Active Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1928-1933.	1.4	1